Factor VIII levels and the risk of pre-eclampsia, HELLP syndrome, pregnancy related hypertension and severe intrauterine growth retardation
Witsenburg, C.P.J.; Rosendaal, F.R.; Middeldorp, J.M.; Meer, F.J.M. van der; Scherjon, S.A.

Citation

Version: Not Applicable (or Unknown)
License:
Downloaded from: https://hdl.handle.net/1887/5055

Note: To cite this publication please use the final published version (if applicable).
Factor VIII levels and the risk of pre-eclampsia, HELLP syndrome, pregnancy related hypertension and severe intrauterine growth retardation

C.P.J. Witsenburg, F.R. Rosendaal, J.M. Middeldorp, F.J.M. Van der Meer, S.A. Scherjon

Department of Obstetrics, Leiden University Medical Center, K6-27, PO Box 9600 2300 RC Leiden, The Netherlands
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
Haemostasis and Thrombosis Research Centre, Leiden University Medical Center, Leiden, The Netherlands

Abstract

Objective: Recently, acquired as well as genetic prothrombotic factors are associated with thrombotic events. These factors have also been related to conditions of uteroplacental insufficiency such as pre-eclampsia, HELLP syndrome and severe intrauterine growth restriction (IUGR). The aim of this study was to determine whether elevated factor VIII levels are associated with uteroplacental insufficiency, in particular pre-eclampsia, HELLP syndrome or pregnancy-induced hypertension and intrauterine growth retardation.

Methods: Plasma samples of 75 women with a history of pregnancy complicated by pre-eclampsia, HELLP syndrome, pregnancy induced hypertension or intrauterine growth restriction were tested for factor VIII:C (FVIII:C) levels at a minimum of 10 weeks post-partum. Laboratory results were compared to factor VIII:C levels found in a healthy control group of 272 women.

Results: Mean factor VIII:C levels were similar at 123 IU/dl in both the patient group and the controls. In a logistic regression model, after adjusting for age and blood group, no effect of factor VIII:C levels on the risk of pregnancy complications was observed, with the exception of IUGR with (OR 2.9, CI 1.0—8.7) or without hypertension (OR 2.0, CI 0.7—6.4).

Conclusion: If the elevated level of factor VIII would be the sole factor responsible for the increased risk observed, one would expect to find an effect of blood group on
Introduction

Approximately 1–5% of all pregnancies are complicated by serious conditions such as pre-eclampsia, HELLP syndrome (haemolysis, elevated liver enzymes and low platelets), solutio placentae, severe intrauterine growth restriction (IUGR), foetal loss and stillbirth [1]. In general, these conditions are thought to be related to a poor trophoblastic invasion of maternal spiral arteries, leading to a syndrome known as uteroplacental insufficiency. The mechanisms of uteroplacental insufficiency are largely unknown and its aetiology is likely to be multicausal: immunological as well as genetic factors may be involved, which may include factors involved in blood clotting [2–5].

Recently, insights in the causes of thrombosis have grown, which include genetic as well as acquired risk factors such as deficiencies of antithrombin, protein C and protein S, activated protein C resistance due to the factor V Leiden mutation and prothrombin G20210A mutation. High levels of procoagulant factors, such as factor VIII, factor IX and factor XI, have also been associated with an increased risk of venous thrombosis [6–11], as has hyperhomocysteinaemia [12–14]. Only recently, these factors have been related to uteroplacental insufficiency. Thrombophilic defects, notably deficiencies of anticoagulant factors, were found in up to 50% of patients with severe pre-eclampsia and HELLP syndrome [3] and they have been associated with an increased risk of stillbirth as well as foetal growth retardation [15,16].

Elevated levels of factor VIII:C (FVIII:C) are a common risk factor for venous thrombosis [17–19]. They may also be associated with an increased risk of arterial thrombosis in coronary heart disease [20,21]. The basis of high levels of FVIII is unclear: it is partly associated with ABO blood group (lower levels in type O) and APC resistance, but additional variation in FVIII levels has been shown to cluster in families too [22]. When a cut-off point for high levels of 150 IU/dl is used the prevalence of elevated FVIII:C is high: 11% of healthy control subjects and 25% of patients with a first episode of deep-vein thrombosis were found to have FVIII:C levels >150 IU/dl [23]. Factor VIII in plasma is bound to von Willebrand factor (VWF) and its levels are to a large degree determined by the levels of VWF, which on its turn are dependent on blood group [24,25]. Elevated levels of FVIII:C in patients with venous thromboembolism have been shown to persist over time [17,31] and independent of acute-phase reactions [17,19,32].

In the 1970s and 1980s, several authors reported an elevated ratio of VWF/FVIII:C during pregnancy and an even higher ratio in pregnancies complicated by pre-eclampsia [26–29] and hypertension [30,31]. Altered coagulation status due to these conditions might increase the factor VIII:C consumption, causing plasma FVIII:C levels to go down. Elevated levels of VWF, which is known to increase in diseases associated with endothelial activation, might add to this effect.

In this study, we set out to determine whether persistent elevated factor VIII:C levels were associated with conditions of uteroplacental insufficiency in a group of 75 women with a history of pregnancy complicated by hypertensive disorders (pre-eclampsia, HELLP syndrome or pregnancy-induced hypertension) or intrauterine growth restriction.

Methods

Patients and study design

Women reporting to our clinic with a history of hypertensive complications or IUGR during a preceding pregnancy are screened for the presence of thrombophilic defects, among which factor VIII:C. Between August 1999 and July 2002 FVIII:C levels were determined in a group of 75 women with one of these complications in their index pregnancy. Plasma FVIII:C levels were measured at a minimum of 10 weeks post-partum, patients using oral contraceptives at the time of testing being excluded. With regard to the different complications of pregnancy 20 of the women had a history of IUGR only, 36 had suffered from hypertensive disorders during pregnancy and 19 women had had a combination of the 2. Laboratory results were compared to factor VIII:C levels found in 272
healthy female controls derived from the Leiden Thrombophilia Study (LETS) [18].

**Definitions**

Pre-eclampsia was defined as pregnancy-induced hypertension (diastolic blood pressure ≥90 mm Hg) plus significant proteinuria (urinary protein excretion >300 mg/24 h or two 2+ or higher readings of on dipstick analysis of midstream or catheter urine samples) after 20 weeks of gestational age. Eclampsia was defined as the occurrence of generalised convulsions during pregnancy, during labour or within 7 days of delivery, not caused by epilepsy or other convulsive disorders. HELLP syndrome was defined as the presence of haemolysis (LDH > 600 IU/l), elevated liver enzymes (SGOT > 70 IU/l) and thrombocytopenia (<100,109/l) [33]. Intrauterine growth restriction finally was defined as a neonatal birth weight below the 10th percentile, while individuals with other causes such as gross chromosomal disorders and viral infections were excluded [34].

**Laboratory tests**

Venous blood samples were taken from the subjects at a minimum of 10 weeks post-partum in 106 mmol/l trisodium citrate. Factor VIII:C levels were determined by a one-stage clotting assay [18].

**Statistical analysis**

The analysis was performed by comparing FVIII:C levels in 75 patients and 272 female population controls. First, we compared mean levels of FVIII:C between cases and controls, with 95% confidence interval for the difference of the means. Subsequently, we calculated odds ratios as a measure for the relative risk, by cross-tabulation and logistic regression for various cut-off values. Odds ratios (and 95% confidence intervals) adjusted for blood type and age were derived from the model.

**Results**

We included 75 patients and 272 controls. Patients had a history of IUGR (n=20), pre-eclampsia, HELLP syndrome or pregnancy induced hypertension (n=36), or a combination of the 2 (n=19). Median age of the patients at the time of the blood draw was 31.6 (range 23.8–44.4 years), while for the controls it was 44.8 years (range 17–72).

In both the patient and control group, mean levels of factor VIII:C were 123 IU/dl. Blood group O was present in 25 (33%) of the patients and 111 (41%) of the control women. When we stratified the patients by ABO blood group, mean FVIII:C levels were 118 IU/dl for blood type O (n=25) and 125 IU/dl for blood type non-O (n=50). In the control

---

### Table 1

Mean FVIII:C levels in patients with a history of pre-eclampsia, HELLP syndrome, pregnancy-induced hypertension and/or IUGR and healthy controls

<table>
<thead>
<tr>
<th>Blood type O</th>
<th>Blood type non-O</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>Mean</td>
<td>95% CI</td>
</tr>
<tr>
<td><strong>Patients</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE/HELLP/HT+IUGR (n=19)</td>
<td>5</td>
<td>121</td>
</tr>
<tr>
<td>IUGR (n=20)</td>
<td>9</td>
<td>113</td>
</tr>
<tr>
<td>PE/HELLP/HT (n=36)</td>
<td>11</td>
<td>120</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>25</td>
<td>118</td>
</tr>
<tr>
<td><strong>Controls</strong></td>
<td>111</td>
<td>110</td>
</tr>
</tbody>
</table>

### Table 2

Mean differences between patients and controls in FVIII:C concentration

<table>
<thead>
<tr>
<th>Blood type O</th>
<th>Blood type non-O</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>Mean difference</td>
<td>95% CI</td>
</tr>
<tr>
<td><strong>PE/HELLP/HT+IUGR (n=19)</strong></td>
<td>5</td>
<td>0.15</td>
</tr>
<tr>
<td>IUGR (n=20)</td>
<td>9</td>
<td>0.11</td>
</tr>
<tr>
<td>PE/HELLP/HT (n=36)</td>
<td>11</td>
<td>0.19</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>25</td>
<td>0.15</td>
</tr>
</tbody>
</table>
group, the mean FVIII:C levels were 110 IU/dl for blood type O (n=111) and 132 IU/dl for non-O (n=161). We also calculated mean factor VIII:C levels for the different complications of pregnancy. Factor VIII levels seemed to be the highest in patients with a history of combined IUGR/hypertensive disorders, the lowest in patients with hypertensive disorders only, and intermediate in patients with IUGR only, although confidence intervals were wide (Table 1).

Mean differences between patients and controls stratified for blood group type are given in Table 2. We only found a difference in factor VIII:C levels in patients with a non-O blood group, particularly in the group of hypertensive patients without foetal growth restriction.

The risk associated with high factor VIII:C levels was estimated stratified for blood group type for each of the pregnancy complications separately, by using factor VIII:C levels of 150 IU/l as a cut-off value. Odds ratios and confidence intervals are given in Table 3. In this comparison to controls, no specific relation is seen between raised FVIII:C levels (>150 IU/l) and the different pregnancy complications for both O and non-O blood group type.

In a multivariate logistic regression model, we assessed the contribution to risk, for each of the complications, of blood group and elevated factor VIII levels, adjusted for age. FVIII:C appeared to increase risk with factor three for hypertensive complications in combination with IUGR (adjusted OR 2.9, CI 1.0—8.7). For IUGR without hypertensive complications, a two-fold increased risk was found (adjusted OR 2.0, CI 0.7—6.3). For hypertensive complications without IUGR, no effect on risk of FVIII:C levels was observed (adjusted OR 1.2, CI 0.5—3.2) (Table 4).

**Discussion**

Given the recently reported association between elevated FVIII levels and thrombotic events, one might expect to find a similar association with regard to pregnancy complications. It was shown that a raised F VIII level is an independent risk factor for early recurrent miscarriage [35]. Other studies have found a raised VWF:Ag/FVIII:C ratio in hypertensive pregnant women [30,31]. This might be caused by either a raised VWF:Ag or a decreased FVIII level. The first suggestion is supported by studies in hypertensive-preeclamptic pregnant women where indeed a raised VWF:Ag level is found [36,37]. In our study, which concentrated on absolute FVIII:C levels, no clear association between FVIII:C levels postpartum and the risk of hypertensive pregnancy complications could be demonstrated. In the subgroup of patients with a history of IUGR with (OR 2.9, CI 1.0—8.7) or without hypertension (OR 2.0, CI 0.7—6.4), we found that raised FVIII:C levels were related to mildly elevated odds ratios with broad confidence intervals.

Mean factor VIII:C levels in the patient group and in the control group were not different. Stratification by ABO blood group led to similar results. For the different complications of pregnancy, FVIII levels were higher in patients with a history of a combined IUGR/hypertensive disorder, lower in patients with hypertensive disorders only and intermediate in patients with IUGR only, but the wide confidence intervals did not allow a firm conclusion.

### Table 3

<table>
<thead>
<tr>
<th>Raised FVIII levels</th>
<th>Blood type O</th>
<th>Blood type non-O</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence OR (95% CI)</td>
<td>Incidence OR (95% CI)</td>
<td></td>
</tr>
<tr>
<td>PE/HELLP/HT+IUGR</td>
<td>20% 1.9 (0.2—18.2)</td>
<td>43% 2.4 (0.8—7.2)</td>
</tr>
<tr>
<td>IUGR</td>
<td>11% 0.9 (0.1—8.2)</td>
<td>36% 1.8 (0.5—6.4)</td>
</tr>
<tr>
<td>PE/HELLP/HT</td>
<td>27% 2.8 (0.7—12.0)</td>
<td>16% 0.6 (0.2—1.8)</td>
</tr>
<tr>
<td>Controls</td>
<td>12% 24%</td>
<td></td>
</tr>
</tbody>
</table>

### Table 4

<table>
<thead>
<tr>
<th>Blood group (unadjusted)</th>
<th>Blood group (adjusted for FVIII)</th>
<th>High FVIII:C (unadjusted)</th>
<th>High FVIII:C (adjusted for blood group)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE/HELLP/HT+IUGR</td>
<td>0.5 (0.2—1.5)</td>
<td>0.6 (0.2—1.9)</td>
<td>3.2 (1.1—9.4)</td>
</tr>
<tr>
<td>IUGR</td>
<td>1.1 (0.4—2.8)</td>
<td>1.2 (0.4—3.3)</td>
<td>2.0 (0.6—6.0)</td>
</tr>
<tr>
<td>PE/HELLP/HT-IUGR</td>
<td>0.7 (0.3—1.4)</td>
<td>0.7 (0.3—1.5)</td>
<td>1.3 (0.5—3.4)</td>
</tr>
<tr>
<td>Total</td>
<td>0.7 (0.4—1.3)</td>
<td>0.8 (0.4—1.4)</td>
<td>1.8 (0.9—3.6)</td>
</tr>
</tbody>
</table>
Clinical manifestations of uteroplacental insufficiency in the mother disappear very shortly after birth. As FVIII:C levels were measured at a minimum of 10 weeks post-partum, it seems unlikely that factor VIII levels were by then still influenced as a result of these conditions. Blood group is an important determining factor in FVIII levels. Therefore, in case elevated FVIII:C was to increase the risk of these complications of pregnancy, one would expect to find an increased risk of non-O blood group on pregnancy complications as well. However, we did not find any effect of blood group, also after correction for FVIII levels, on the risk for one of the studied complications of pregnancy. This makes a causal relation between FVIII and uteroplacental insufficiency less likely.

In the multivariate logistic regression model, elevated factor VIII levels were associated with a two- to three-fold increased risk of IUGR. Again, the sample size precludes definite conclusions, but one is tempted to speculate that elevated levels of FVIII have a common background with the causes of placental insufficiency. In general, these conditions are thought to be related to a poor trophoblastic invasion of maternal spiral arteries. The mechanisms of uteroplacental insufficiency are largely unknown, but factors involved in blood clotting might well contribute to its aetiology [2—5]. Previous studies have shown an increased risk of pre-eclampsia in women with a low APC-sensitivity ratio, i.e., some form of APC-resistance, in the absence of factor V Leiden [22]. It is also known that factor VIII levels and APC-sensitivity ratios are inversely related, i.e., high factor VIII levels are associated with APC-resistance. It is likely that this represents increased thrombin generation, but, since we observed no effect from ABO-blood group, that this is acquired rather than genetically determined.

References

[22] Clark P, Sattar N, Walker ID, Greer IA. The Glasgow Outcome, APCR and Lipid (GOAL) Pregnancy Study: signifi-


